Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 32,154	$ 24,647
Marketable securities	37,072	70,323
Prepaid and other current assets	2,650	1,212
Total current assets	71,876	96,182
Property and equipment, net	296	62
Acquired license-intangible, net	334	0
Other assets	528	764
Total assets	73,034	97,008
Liabilities
Accounts payable	2,655	1,934
Accrued liabilities	3,728	2,589
Total current liabilities	6,383	4,523
Other long-term liabilities	327	485
Total liabilities	6,710	5,008
Commitments and Contingencies (Note 14)
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.000067 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2022 and December 31, 2021, respectively	0	0
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,866,799 and 3,986,719 shares, at December 31, 2022 and December 31, 2021, respectively; and outstanding, 7,866,061 and 3,985,981 shares, at December 31, 2022 and December 31, 2021, respectively	8	4
Additional paid-in capital	574,548	546,044
Treasury stock, at cost; 738 shares at December 31, 2022 and December 31, 2021 respectively	(708)	(708)
Accumulated deficit	(507,241)	(453,016)
Accumulated other comprehensive loss	(29)	(70)
Total Lisata Therapeutics, Inc. stockholders' equity	66,578	92,254
Non-controlling interests	(254)	(254)
Total equity	66,324	92,000
Total liabilities, non-controlling interests and equity	$ 73,034	$ 97,008